Exploring the synergy between copper and antifungals

Abstract

"Invasive fungal infections (IFIs) are a major health concern, affecting many people worldwide and causing more than 1.2 million deaths per year. Most hospital-acquired IFIs are caused by Candida species, which are natural colonizers of the human microbiota, but can become pathogenic under specific medical contexts. Candida albicans accounts for approximately 50% of all clinical isolates from patients with invasive candidiasis. However, the widespread use of antifungal therapy has favoured the selection of Candida species that are less susceptible to antifungals, such as Candida glabrata. In this sense, finding novel antifungal targets or/and improving the efficacy of currently available drugs is of urgent and utmost importance.(...)".